Literature DB >> 12908468

Bortezomib.

Andrew Paramore1, Simon Frantz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12908468     DOI： 10.1038/nrd1159

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  51 in total

Review 1.  Peptidomimetics in cancer chemotherapy.

Authors:  C Avendaño; J C Menéndez
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

2.  Molecular pathways: turning proteasomal protein degradation into a unique treatment approach.

Authors:  Sebastian Stintzing; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

3.  A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.

Authors:  C Zhao; X Chen; D Zang; X Lan; S Liao; C Yang; P Zhang; J Wu; X Li; N Liu; Y Liao; H Huang; X Shi; L Jiang; X Liu; Z He; Q P Dou; X Wang; J Liu
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

4.  Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

Authors:  Paige Dickson; Daniel Abegg; Ekaterina Vinogradova; Junichiro Takaya; Hongchan An; Scott Simanski; Benjamin F Cravatt; Alexander Adibekian; Thomas Kodadek
Journal:  Cell Chem Biol       Date:  2020-08-27       Impact factor: 8.116

5.  Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.

Authors:  G S Falchook; M Duvic; D S Hong; J Wheler; A Naing; J Lim; R Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-29       Impact factor: 3.333

6.  A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.

Authors:  Darci J Trader; Scott Simanski; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2015-05-08       Impact factor: 15.419

7.  Isolation and structure determination of a proteasome inhibitory metabolite from a culture of Scytonema hofmanni.

Authors:  Sang Hee Shim; George Chlipala; Jimmy Orjala
Journal:  J Microbiol Biotechnol       Date:  2008-10       Impact factor: 2.351

Review 8.  Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.

Authors:  Jeffrey I Cohen; Catherine M Bollard; Rajiv Khanna; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

9.  Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

Authors:  Michael Frezza; Sarmad Sahiel Hindo; Dajena Tomco; Marco M Allard; Qiuzhi Cindy Cui; Mary Jane Heeg; Di Chen; Q Ping Dou; Cláudio N Verani
Journal:  Inorg Chem       Date:  2009-07-06       Impact factor: 5.165

10.  Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency.

Authors:  Enrica Ek Tan; Richard A Hopkins; Chrissie K Lim; Saumya S Jamuar; Christina Ong; Koh C Thoon; Mark Ja Koh; Eun Mong Shin; Derrick Wq Lian; Madhushanee Weerasooriya; Christopher Zw Lee; Andreas Alvin Pumomo Soetedjo; Chang Siang Lim; Veonice B Au; Edmond Chua; Hui Yin Lee; Leigh Ann Jones; Sharmy S James; Nivashini Kaliaperumal; Jeffery Kwok; Ee Shien Tan; Biju Thomas; Lynn Xue Wu; Lena Ho; Anna Marie Fairhurst; Florent Ginhoux; Adrian Kk Teo; Yong Liang Zhang; Kok Huar Ong; Weimiao Yu; Byrappa Venkatesh; Vinay Tergaonkar; Bruno Reversade; Keh Chuang Chin; Ah Moy Tan; Woei Kang Liew; John E Connolly
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.